Free Trial

Belluscura (BELL) Competitors

GBX 0.75 0.00 (0.00%)
As of 10/16/2025

BELL vs. AVO, RUA, SUN, POLX, MHC, DEMG, SN, NIOX, MXCT, and EKF

Should you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), Polarean Imaging (POLX), MyHealthChecked (MHC), Deltex Medical Group (DEMG), Smith & Nephew (SN), NIOX Group (NIOX), MaxCyte (MXCT), and EKF Diagnostics (EKF). These companies are all part of the "medical devices" industry.

Belluscura vs. Its Competitors

Belluscura (LON:BELL) and Advanced Oncotherapy (LON:AVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

0.7% of Belluscura shares are held by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are held by institutional investors. 7.1% of Belluscura shares are held by company insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Advanced Oncotherapy has a net margin of 0.00% compared to Belluscura's net margin of -1,030.73%. Advanced Oncotherapy's return on equity of -67.34% beat Belluscura's return on equity.

Company Net Margins Return on Equity Return on Assets
Belluscura-1,030.73% -102.62% -43.53%
Advanced Oncotherapy N/A -67.34%-11.73%

Belluscura has higher revenue and earnings than Advanced Oncotherapy. Belluscura is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Belluscura£1.80M1.67-£29.55M-£13.10-0.06
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A

Belluscura has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Advanced Oncotherapy has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500.

In the previous week, Belluscura's average media sentiment score of 0.00 equaled Advanced Oncotherapy'saverage media sentiment score.

Company Overall Sentiment
Belluscura Neutral
Advanced Oncotherapy Neutral

Summary

Advanced Oncotherapy beats Belluscura on 6 of the 10 factors compared between the two stocks.

Get Belluscura News Delivered to You Automatically

Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BELL vs. The Competition

MetricBelluscuraMedical Devices IndustryMedical SectorLON Exchange
Market Cap£3.01M£2.57B£6.19B£2.57B
Dividend YieldN/A2.44%5.70%5.37%
P/E Ratio-0.06190.3185.624,237.12
Price / Sales1.67131.80615.4999,406.89
Price / Cash8.0015.9937.1027.90
Price / Book0.063.8312.238.11
Net Income-£29.55M£132.05M£3.33B£5.89B
7 Day PerformanceN/A2.79%1.17%-0.62%
1 Month PerformanceN/A3.85%6.85%0.73%
1 Year Performance-93.32%17.68%58.93%128.71%

Belluscura Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BELL
Belluscura
N/AGBX 0.75
flat
N/AN/A£3.01M£1.80M-0.0624
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/A-25.003,900Gap Down
RUA
RUA Life Sciences
N/AGBX 11
-4.3%
N/A-21.3%£7.14M£4.11M-2.6148Gap Down
SUN
Surgical Innovations Group
N/AGBX 0.60
+4.2%
N/A+2.7%£5.36M£11.92M-383.9780Gap Up
POLX
Polarean Imaging
N/AGBX 0.47
+10.1%
N/A-70.0%£5.13M£2.56M-468.0028Gap Down
MHC
MyHealthChecked
N/AGBX 9.07
-9.3%
N/A-52.9%£4.72M£3.22M-241.1216Gap Down
DEMG
Deltex Medical Group
N/AN/AN/AN/A£187K£1.76M-0.1537Gap Up
High Trading Volume
SN
Smith & Nephew
3.1857 of 5 stars
GBX 1,324.50
-2.4%
GBX 1,379.33
+4.1%
+20.2%£14.52B£7.08B47.6918,452High Trading Volume
NIOX
NIOX Group
N/AGBX 74.60
+0.8%
GBX 90
+20.6%
+9.4%£309.22M£46M5,968.0092
MXCT
MaxCyte
N/AGBX 1.62
-4.7%
N/A-99.4%£170.11M£35.75M-4.0580Positive News
High Trading Volume
EKF
EKF Diagnostics
N/AGBX 28.80
-5.6%
N/A-5.6%£136.97M£50.22M2,133.33356Gap Down

Related Companies and Tools


This page (LON:BELL) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners